Patient International Normalised Ratio (INR) Self-Testing Program
NCT ID: NCT00925197
Last Updated: 2009-06-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
206 participants
INTERVENTIONAL
2004-05-31
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Benefit of Self-monitoring of Anticoagulation Instrument
NCT00506870
Choice of Valve Substitute in the Era of Oral Anticoagulation Self-Management
NCT01269905
Outcome, Recuperation and Hemodynamics in Aortic Stenosis
NCT05272020
Assessment of Clinical Onset of IV Heparin in Interventional Cardiology and Cardiac Surgery
NCT04785885
The Dutch Asymptomatic Mitral Regurgitation Trial
NCT01708265
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients (206) were postoperatively, randomly, consecutively included (2004 - 2008): 103 patients in each group, with a one year follow-up. Two INR control devices were selected: Coaguchek® (Roche) and INRATIO® (Hemosense).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
INR self-testing program
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients fitted with one or more mechanical heart valves either alone or in combination with myocardial revascularization
* oral anticoagulant treatment
* patients with social security cover
* written informed consent signed by both patient and investigator
* able to be followed up during 12 months
Exclusion Criteria
* Participation in another clinical study
* Patient is pregnant or nursing
* Life expectancy less than three months
* Contra-indication of to an A.V.K treatment
* Difficult comprehension of the French language
* Patients unable to master the self-monitoring procedures
* Individuals under judicial control or enquiry
* Patients on dialysis Patients with incomplete understanding of instructions
* Blind patients and those unable to read
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott Medical Devices
INDUSTRY
Roche Diagnostics GmbH
INDUSTRY
HemoSense
INDUSTRY
University Hospital, Clermont-Ferrand
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CHU Clermont-Ferrand
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kasra Azarnoush, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Clermont-Ferrand
References
Explore related publications, articles, or registry entries linked to this study.
Azarnoush K, Dorigo E, Pereira B, Dauphin C, Geoffroy E, Dauphin N, D'Ostrevy N, Legault B, Camilleri L. Mid-term results of self-testing of the international normalized ratio in adults with a mechanical heart valve. Thromb Res. 2014 Feb;133(2):149-53. doi: 10.1016/j.thromres.2013.09.013. Epub 2013 Sep 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHU-0054
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.